Viral Vector Manufacturing Market Overview
Global Viral Vector Manufacturing Market reached USD 0.9 billion in 2022 and is expected to reach USD 3.8 billion by 2031 growing with a CAGR of 20.3% during the forecast period 2024-2031. The global viral vector manufacturing market has witnessed significant growth in recent years.
The global viral vector manufacturing market has witnessed significant growth in recent years. Viral vectors are essential tools for delivering therapeutic genes into target cells and are used in a wide range of diseases, including cancer, genetic disorders, and viral infections. Additionally, advancements in manufacturing technologies, such as suspension cell culture systems and transient transfection methods, are improving the scalability and efficiency of viral vector production. The market is expected to continue its improvements in the coming years.
The global viral vector manufacturing market is driven by the factors such as the increasing adoption of gene and cell therapies, the increasing number of clinical trials in this field, advancements in gene therapies, and technological advancements in viral vector manufacturing.
Viral Vector Manufacturing Market Scope
| Metrics | Details |
| CAGR | 20.3% |
| Size Available for Years | 2022-2031 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (USD ) |
| Segments Covered | Type, Disease, Application, End-User, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Infection Type Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
To Get a Free Sample Click here
Viral Vector Manufacturing Market Dynamics
Increasing Adoption of Gene and Cell Therapies Drives the Growth of the Viral Vector Manufacturing Market
Gene and cell therapies have gained significant attention in recent years due to their potential to treat a wide range of diseases, including genetic disorders, cancer, and rare diseases. Viral vectors are crucial components of these therapies as they facilitate the delivery of therapeutic genes into target cells. The growing adoption of gene and cell therapies is driving the demand for viral vectors, thus propelling market growth.
For instance, in January 2023, CDMO Startup Vector BioMed developed a technology platform for designing and manufacturing the lentiviruses used to deliver cell and gene therapies. The startup is launching as the field continues to experience shortages of these viral vectors.
As more gene therapies receive regulatory approvals and enter clinical practice, the demand for viral vectors is boosted. This growing adoption is driven by the significant clinical benefits demonstrated by gene therapies in various diseases, including genetic disorders, cancer, and rare diseases. The ability of gene therapies to provide long-term or potentially curative treatment options for patients who have limited or no other alternatives has fueled their adoption.
For instance, on July 3, 2023, Skyline Therapeutics, an innovation-driven gene therapy company committed to developing unique and novel solutions for rare and severe diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Phase I/IIa clinical trial of SKG0106, a one-time intravitreally delivered AAV gene therapy for the treatment of neovascular age-related macular degeneration (nAMD).
Increasing Demand for Viral Vectors in Research Also Drives the Growth of the Viral Vector Manufacturing Market
Viral vectors are considered as important tool in various areas of research. They are used to deliver genes into cells to study gene function, protein expression, and molecular pathways. Viral vectors are employed in fields such as functional genomics, stem cell research, cancer biology, neuroscience, and immunology. As scientific research expands and new discoveries are made, the demand for viral vectors in research applications is expected to grow.
For instance, in November 2022, PerkinElmer, Inc., a global leader committed to innovating for a healthier world, launched ready-to-use Adeno-associated Virus Vectors (AAV) Detection Kits to support researchers working on gene therapies for a variety of serious diseases. The high-throughput viral assays are designed to help researchers quickly and easily characterize viral vector particles being produced to enable decision-making for safe and efficient gene transfer.
Viral vectors also play a crucial role in drug discovery and development processes. They are utilized to validate drug targets, test the efficacy of therapeutic candidates, and assess safety profiles. Viral vectors help researchers better understand disease mechanisms, design and optimize therapies and identify potential biomarkers. As pharmaceutical and biotechnology companies intensify their drug discovery efforts, the demand for viral vectors as research tools is likely to increase.
High Manufacturing Costs Will Hamper the Growth of the Market.
Viral vector manufacturing involves complex and costly processes. The production of viral vectors requires specialized facilities, equipment, and skilled personnel, which contributes to high manufacturing costs. The expenses associated with quality control, purification, and characterization of viral vectors further add to the overall cost. These high manufacturing costs can limit the accessibility and affordability of viral vectors, hindering market growth.
Viral Vector Manufacturing Market Segment Analysis
The global viral vector manufacturing market is segmented based on type, disease, application, end-user, and region.
The Adenoviral Vectors Segment Accounted for Approximately 37.7% of the Viral Vector Manufacturing Market Share
Adenoviral vectors have demonstrated their utility in various therapeutic areas, including cancer, cardiovascular diseases, genetic disorders, and infectious diseases. Their ability to efficiently transduce a wide range of dividing and non-dividing cells makes them attractive for gene delivery purposes. Additionally, adenoviral vectors can accommodate larger genetic payloads, allowing the delivery of larger therapeutic genes.
Moreover, adenoviral vectors have been extensively studied and optimized, leading to advancements in manufacturing technologies and techniques specific to these vectors. These advancements have facilitated the large-scale production of adenoviral vectors with improved yield and quality, addressing some of the challenges associated with viral vector manufacturing.
For instance, in May 2023, Oxford Biomedica plc, a quality and innovation-led viral vector CDMO, announces the launch of its 4th generation lentiviral vector delivery system, TetraVectaTM. This state-of-the-art technology developed at Oxford Biomedica elevates the quality, potency, and packaging capacity of lentiviral vectors, while incorporating new and enhanced safety features, adding to the Company’s client offering and its leading LentiVector platform. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), and adenoviral vectors.
Source: DataM Intelligence Analysis (2023)
Viral Vector Manufacturing Market Geographical Share
North America Accounted for Approximately 39.8% of the Market Share in 2022, Owing to the Presence of Major Players and Advanced Healthcare Infrastructure
The presence of major players in the viral vector manufacturing industry, including pharmaceutical companies, biotechnology firms, and contract development and manufacturing organizations. North America has a robust biopharmaceutical industry and a strong focus on research and development activities related to gene and cell therapies. The presence of these key players with expertise in viral vector manufacturing has boosted the market in the region.
Additionally, North America benefits from advanced healthcare infrastructure and a supportive regulatory environment. The United States, in particular, has regulatory agencies such as the Food and Drug Administration (FDA) that have established frameworks and expedited pathways for the development and approval of gene therapies and viral vector-based products. The regulatory environment in North America has been conducive to innovation and commercialization, attracting investments and fostering growth in the viral vector manufacturing market.
For instance, in May 2023, the Canadian Advanced Therapies Training Institute (CATTI) announced that it has launched a cell and gene therapy (CGT) training center of excellence at the University of Guelph in Guelph, Ontario, Canada through a partnership with the university, CCRM, a Canada-based public–private partnership, and OmniaBio, a subsidiary of CCRM and a contract development and manufacturing organization specializing in the production and manufacturing of gene-modified cells and viral vectors.
Source: DataM Intelligence Analysis (2023)
Viral Vector Manufacturing Market Companies
The major global players in the viral vector manufacturing market include Sanofi SA, Thermo Fisher Scientific Inc., Cobra Biologics Ltd, Lonza Group Ltd, Merck & Co., Oxford BioMedica, CGT Catapult, UniQure NV, FUJIFILM Diosynth Biotechnologies, and Spark Therapeutics Inc.
COVID-19 Impact on Viral Vector Manufacturing Market
The COVID-19 pandemic significantly impacted the global viral vector manufacturing market. The pandemic has created a surge in demand for viral vectors, particularly in the development and production of COVID-19 vaccines. Viral vectors, such as adenoviral vectors, have been widely used as delivery platforms for COVID-19 vaccine candidates. The urgent need for large-scale manufacturing of these vectors to support vaccine development has led to increased demand and pressure on viral vector manufacturing capabilities.
Russia-Ukraine Conflict Analysis
The Russia-Ukraine conflict is estimated to have a moderate impact on the global viral vector manufacturing market. The conflict between Russia and Ukraine may disrupt global supply chains, including those involved in viral vector manufacturing. Ukraine is a significant producer of raw materials, chemicals, and pharmaceutical products used in the biopharmaceutical industry. Any disruptions in the supply of these critical components could affect the manufacturing processes and production capacity of viral vectors globally.
By Type
- Retroviral Vectors
- Adenoviral Vectors
- Adeno-Associated Viral Vectors
- Others
By Disease
- Cancer
- Genetic Disorders
- Infectious Diseases
- Others
By Application
- Gene Therapy
- Vaccinology
By End-User
- Pharmaceutical and Biopharmaceutical Companies
- Research Institutes
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
Key Developments
- On June 29, 2023, Donaldson Company, Inc., a leading worldwide provider of innovative filtration products and solutions, announced the acquisition of Univercells Technologies, a global producer of innovative biomanufacturing solutions for cell and gene therapy research, development, and commercial manufacturing.
- On June 12, 2023, Charles River Laboratories International, Inc. and Curigin, a Korean biotechnology company developing innovative oncolytic ribonucleic acid interference (RNAi) gene therapies, announced a collaboration for adenoviral vector production. The gene therapy developer will leverage Charles River's market-leading expertise in contract development and manufacturing organization (CDMO) solutions to support its preclinical and clinical trials.
- On June 29, 2023, Albumedix Ltd., an enabler of advanced therapies and the world leader in recombinant human albumin (rAlb), announced that they have entered into a collaboration agreement with Cell and Gene Therapy Catapult to investigate the use of Albumedix´ proprietary albumin-based solutions for advanced therapy applications, including viral vectors manufacturing.
Why Purchase the Report?
- To visualize the global viral vector manufacturing market segmentation based on type, disease, application, end-user, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of viral vector manufacturing market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global viral vector manufacturing market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
